Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185353 | 0.91 | PTGDR2 (0.40) | CCR3ALDH1A1SMN1; SMN2ACSL1PTGDR2 | |
| SCHEMBL10186424 | 0.90 | ALDH1A1 (0.46) | NPC1ALDH1A1SMN1; SMN2ACSL1PTGDR2 | |
| SCHEMBL10186131 | 0.89 | NPC1 (0.49) | CHRM1CHRM5CCR3GRM5NPC1 | |
| SCHEMBL10186162 | 0.89 | CCR3 (0.44) | CCR3ALDH1A1ACSL1PTGDR2 | |
| SCHEMBL10185105 | 0.89 | CCR3 (0.49) | CCR3NPC1RAB9AACSL1PTGDR2 | |
| SCHEMBL10185364 | 0.89 | CCR3 (0.44) | CHRM5CCR3SLC5A7MEN1KMT2A | |
| SCHEMBL10185361 | 0.88 | SLC5A7 (0.42) | CCR3SLC5A7MEN1KMT2ANPC1 | |
| SCHEMBL10184386 | 0.87 | CCR3 (0.42) | CCR3SLC5A7MEN1KMT2ANPC1 | |
| SCHEMBL10184943 | 0.87 | DGAT1 (0.46) | SLC5A7RAB9AACSL1 | |
| SCHEMBL10186165 | 0.86 | CCR3 (0.43) | CHRM1CCR3SLC5A7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | CHRM1 2527/4885CHRM5 3681/4885CCR3 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.